Aditxt regains Nasdaq minimum bid price compliance, removes panel monitoring

Aditxt, Inc.

Regained full compliance with Nasdaq listing requirements; no longer under panel monitoring.
Adimune subsidiary targeting IND/CTA filing for human trials in Q3/Q4 2025 for psoriasis and Type 1 diabetes.
Pearsanta plans commercial launch of prostate cancer and endometriosis tests in H2 2025.
Working to close Appili and Evofem acquisitions; capital and restructuring needed.
CEO reports approximately 40,000-50,000 shareholders globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.